International

The search for 2021’s inductees into the IP Hall of Fame is underway

Nomination process now open with a new category introduced in memory of Todd Dickinson

The search for 2021’s inductees into the IP Hall of Fame is underway
What life sciences businesses need to know about data commercialisation
25 Feb 2021

What life sciences businesses need to know about data commercialisation

A strategy for protecting and exploiting data is now a must for entities involved in healthcare research

How hub-and-spoke businesses are creating new pharma IP monetisation models
23 Feb 2021

How hub-and-spoke businesses are creating new pharma IP monetisation models

The launch of Centessa is the latest development in a trend that has big implications for the monetisation of unpartnered or deprioritised IP-backed pharma assets

Latest

View all
18 Feb 2021

Seven top IP tips for biotech SMEs

How smaller biotechs can best overcome pitfalls and maximise the value of their inventions Read more

9 Feb 2021

Five IP takeaways from Jazz Pharmaceuticals’ $7 billion medical cannabis buyout

A major milestone in the medical cannabinoid patent market has been passed Read more

19 Jan 2021

Six life sciences IP dealmaking trends to watch out for in 2021

Despite a turbulent 2020 for pharma transactions, it is possible to discern a few patterns for activity in the market this year Read more

22 Dec 2020

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies. Read more

Designs

View all
20 May 2020

IP Hall of Fame 2020 inductees announced

A UK Supreme Court justice, a former USPTO acting director, a globally-renowned IP scholar, a trailblazing trademark lawyer and a one-time presidential candidate form the class of 2020 Read more

28 Apr 2020

How IP owners have responded to the covid-19 challenge so far

Several innovators have already waived exclusivities, but big decisions for right holders lie ahead Read more

26 Mar 2020

Final call to take part in this year’s IAM benchmarking survey

Help us to identify the key trends currently shaping the global IP market Read more

18 Feb 2020

Tell us what you think of the latest developments in the global IP market

IAM's annual IP benchmarking survey opens today Read more

Finance

View all
26 Mar 2020

Final call to take part in this year’s IAM benchmarking survey

Help us to identify the key trends currently shaping the global IP market Read more

18 Mar 2020

Help us map the latest developments in the global IP market

There’s not long left to answer our annual IP benchmarking survey Read more

18 Feb 2020

Tell us what you think of the latest developments in the global IP market

IAM's annual IP benchmarking survey opens today Read more

13 Feb 2019

IPBC Global 2019 is shaping up to be the biggest and best of the series so far

Senior decision makers from a wide range of companies are already confirmed to attend as demand for tickets exceeds the rate for last year's sell-out event in San Francisco Read more

Frand/SEPS

View all
26 Mar 2020

Final call to take part in this year’s IAM benchmarking survey

Help us to identify the key trends currently shaping the global IP market Read more

18 Mar 2020

Help us map the latest developments in the global IP market

There’s not long left to answer our annual IP benchmarking survey Read more

28 Feb 2020

The US has a mountain to climb in 5G network equipment

Patent analysis shows that American companies would need to make big plays if they want to catch the Chinese, but it is almost certainly too late already Read more

18 Feb 2020

Tell us what you think of the latest developments in the global IP market

IAM's annual IP benchmarking survey opens today Read more

Law & Policy

View all
19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

9 Nov 2020

Pfizer’s covid vaccine found 90% effective, but raises IP questions

Company CEO proclaims “a great day for science and humanity”, but there are patent, know-how and data uncertainties to overcome Read more

20 Oct 2020

Proposal to waive TRIPS is the latest sign of deepening global IP rifts over covid-19

WHO-backed proposal seeks to suspend key multilateral protections for patents and trade secrets Read more

15 Oct 2020

Despite the praise, there may be less to Moderna’s covid patent pledge than meets the eye

The leading vaccine innovator has won plaudits for its commitment not to enforce its coronavirus-related IP rights against other mRNA inventors Read more

Litigation

View all
19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

15 Oct 2020

Despite the praise, there may be less to Moderna’s covid patent pledge than meets the eye

The leading vaccine innovator has won plaudits for its commitment not to enforce its coronavirus-related IP rights against other mRNA inventors Read more

20 Aug 2020

Potential breakthrough covid vaccine faces even greater IP uncertainties

Both private and state entities may own a slice of Moderna’s lucrative late-stage treatment Read more

4 Aug 2020

After PTAB upholds key patent, covid-19 vaccine fight heads to court

Moderna set to face infringement battle over its mRNA-1273, a hot prospect in the fight against coronavirus Read more

Market Developments

View all
16 Dec 2020

Five key insights into 2020’s drug royalty transactions

It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver Read more

19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

10 Nov 2020

There has never been a better time to sell or buy drug royalties, says industry veteran

IAM speaks to leading deal-maker David MacNaughtan about his new fund and the growth of this form of life sciences IP monetisation Read more

8 Oct 2020

The patent system’s social contract has broken down, says IP billionaire Dr Gary Michelson

Spinal surgery pioneer tells IAM that it is important to ensure the US public does not get a rough deal from rights owners Read more

Non-Practising Entities

View all
16 Dec 2020

Five key insights into 2020’s drug royalty transactions

It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver Read more

10 Nov 2020

There has never been a better time to sell or buy drug royalties, says industry veteran

IAM speaks to leading deal-maker David MacNaughtan about his new fund and the growth of this form of life sciences IP monetisation Read more

27 Aug 2020

Translational research key to realising value of university IP, says UCL biopharma chief

Dr Richard Fagan of University College London Business tells IAM about the process of turning patents for early-stage research into investable assets Read more

13 Aug 2020

It’s not all bad news for biopharma IP monetisation during coronavirus slowdown

Oncology licensing, smaller acquisitions and abundant venture capital provide means of commercialising innovation during M&A decline Read more

Patent Pools

View all
19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

23 Jun 2020

Big Pharma facing shortage of late-stage assets as M&A dries up

Pandemic has thrown a spanner in the works for large life sciences companies, which have fewer phase three novel drugs than at any point in the last decade Read more

18 Jun 2020

Takeda offloads yet more “non-core” assets with other deals likely to follow

The Japanese big pharma continues to divest drug rights to pay down its debt and fund desperately needed innovation Read more

Patents Law

View all
16 Dec 2020

Five key insights into 2020’s drug royalty transactions

It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver Read more

19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

10 Nov 2020

There has never been a better time to sell or buy drug royalties, says industry veteran

IAM speaks to leading deal-maker David MacNaughtan about his new fund and the growth of this form of life sciences IP monetisation Read more

9 Nov 2020

Pfizer’s covid vaccine found 90% effective, but raises IP questions

Company CEO proclaims “a great day for science and humanity”, but there are patent, know-how and data uncertainties to overcome Read more

Strategy

View all
16 Dec 2020

Five key insights into 2020’s drug royalty transactions

It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver Read more

19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

9 Nov 2020

Pfizer’s covid vaccine found 90% effective, but raises IP questions

Company CEO proclaims “a great day for science and humanity”, but there are patent, know-how and data uncertainties to overcome Read more

20 Oct 2020

Proposal to waive TRIPS is the latest sign of deepening global IP rifts over covid-19

WHO-backed proposal seeks to suspend key multilateral protections for patents and trade secrets Read more

Technology Licensing

View all
16 Dec 2020

Five key insights into 2020’s drug royalty transactions

It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver Read more

10 Nov 2020

There has never been a better time to sell or buy drug royalties, says industry veteran

IAM speaks to leading deal-maker David MacNaughtan about his new fund and the growth of this form of life sciences IP monetisation Read more

9 Nov 2020

Pfizer’s covid vaccine found 90% effective, but raises IP questions

Company CEO proclaims “a great day for science and humanity”, but there are patent, know-how and data uncertainties to overcome Read more

20 Oct 2020

Proposal to waive TRIPS is the latest sign of deepening global IP rifts over covid-19

WHO-backed proposal seeks to suspend key multilateral protections for patents and trade secrets Read more

Trade Secrets

View all
19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

9 Nov 2020

Pfizer’s covid vaccine found 90% effective, but raises IP questions

Company CEO proclaims “a great day for science and humanity”, but there are patent, know-how and data uncertainties to overcome Read more

20 Oct 2020

Proposal to waive TRIPS is the latest sign of deepening global IP rifts over covid-19

WHO-backed proposal seeks to suspend key multilateral protections for patents and trade secrets Read more

8 Oct 2020

The patent system’s social contract has broken down, says IP billionaire Dr Gary Michelson

Spinal surgery pioneer tells IAM that it is important to ensure the US public does not get a rough deal from rights owners Read more

Valuation

View all
16 Dec 2020

Five key insights into 2020’s drug royalty transactions

It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver Read more

19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

10 Nov 2020

There has never been a better time to sell or buy drug royalties, says industry veteran

IAM speaks to leading deal-maker David MacNaughtan about his new fund and the growth of this form of life sciences IP monetisation Read more

9 Nov 2020

Pfizer’s covid vaccine found 90% effective, but raises IP questions

Company CEO proclaims “a great day for science and humanity”, but there are patent, know-how and data uncertainties to overcome Read more

Find an expert